A078160 Stock Overview
MEDIPOST Co., Ltd. engages in the cord blood bank business in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
MEDIPOST Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,110.00 |
| 52 Week High | ₩15,700.00 |
| 52 Week Low | ₩6,590.00 |
| Beta | 0.58 |
| 1 Month Change | 1.28% |
| 3 Month Change | -2.47% |
| 1 Year Change | -51.80% |
| 3 Year Change | -78.84% |
| 5 Year Change | -78.90% |
| Change since IPO | -65.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| A078160 | KR Healthcare | KR Market | |
|---|---|---|---|
| 7D | 0.6% | -0.9% | 0.6% |
| 1Y | -51.8% | 20.4% | 6.9% |
Return vs Industry: A078160 underperformed the KR Healthcare industry which returned 20.4% over the past year.
Return vs Market: A078160 underperformed the KR Market which returned 6.9% over the past year.
Price Volatility
| A078160 volatility | |
|---|---|
| A078160 Average Weekly Movement | 3.8% |
| Healthcare Industry Average Movement | 5.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A078160 has not had significant price volatility in the past 3 months.
Volatility Over Time: A078160's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 289 | n/a | www.medi-post.co.kr |
MEDIPOST Co., Ltd. engages in the cord blood bank business in South Korea and internationally. The company operates through three divisions: Cord Blood Bank, Stem Cell Therapy, and Health Functional Food. It operates cord blood bank under the CELLTREE name.
MEDIPOST Co., Ltd. Fundamentals Summary
| A078160 fundamental statistics | |
|---|---|
| Market cap | ₩242.44b |
| Earnings (TTM) | ₩5.84b |
| Revenue (TTM) | ₩68.64b |
41.5x
P/E Ratio3.5x
P/S RatioIs A078160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A078160 income statement (TTM) | |
|---|---|
| Revenue | ₩68.64b |
| Cost of Revenue | ₩28.46b |
| Gross Profit | ₩40.18b |
| Other Expenses | ₩34.34b |
| Earnings | ₩5.84b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 171.27 |
| Gross Margin | 58.54% |
| Net Profit Margin | 8.51% |
| Debt/Equity Ratio | 2.8% |
How did A078160 perform over the long term?
See historical performance and comparison